Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222933 | 0.83 | HTR2C (0.37) | MEN1KMT2A | |
| SCHEMBL2948 | 0.72 | — | — | |
| SCHEMBL28776095 | 0.70 | — | — | |
| SCHEMBL6221770 | 0.69 | MEN1 (0.46) | MEN1KMT2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL31438617 | 0.69 | MEN1 (0.46) | MEN1KMT2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL223759 | 0.68 | ALDH1A1 (0.45) | MEN1KMT2APDE3BPDE3AKDM4E | |
| SCHEMBL7914941 | 0.65 | MEN1 (0.52) | MEN1KMT2AKDM4EMAPTNQO2 | |
| SCHEMBL1808685 | 0.65 | MEN1 (0.52) | MEN1KMT2AKDM4EMAPTNQO2 | |
| SCHEMBL14482014 | 0.65 | MEN1 (0.52) | MEN1KMT2ANQO2 | |
| SCHEMBL31274423 | 0.65 | MEN1 (0.52) | MEN1KMT2AKDM4EMAPTNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150222-A1 | IONIZABLE LIPIDS AND NANOPARTICLES COMPRISING SAME | MANA BIO LTD. (IL) | 2024-07-18 | — | — | WO | disclosed |
| CN-118284426-A | Ophthalmic compositions and methods of use thereof | 塔西亚制药公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2024134657-A1 | PYRROLOPYRIDINE AND PYRROLOPYRIDAZINE BASED COMPOUNDS AND USE THEREOF AS PKR INHIBITORS | PROTEKT THERAPEUTICS LTD. (IL) | 2024-06-27 | — | — | WO | disclosed |
| EP-4376837-A1 | COMPOUNDS FOR NEUTROPHIL ROS INHIBITION | Immunyx Pharma Ltd. (IL) | 2024-06-05 | — | — | EP | disclosed |
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-05-16 | — | — | US | disclosed |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | BIOND BIOLOGICS LTD. (IL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024069634-A1 | MICROTUBULE TARGETING AGENTS | Ariel Scientific Innovations Ltd. (IL) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024052923-A1 | IONIZABLE LIPIDS AND COMPOSITIONS COMPRISING SAME | BARCODE NANOTECH LTD. (IL) | 2024-03-14 | — | — | WO | disclosed |
| EP-4326332-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | Biond Biologics Ltd. (IL) | 2024-02-28 | — | — | EP | disclosed |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| US-6127515-A | Functionalized resin for the synthesis of amides and peptides | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-03 | — | — | US | disclosed |
| WO-2000040547-A1 | α-SUBSTITUTION OF UNPROTECTED β-AMINO ESTER COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000032590-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999067192-A2 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDE, KETONE, OXIME, AMINE, HYDROXAMIC ACID AND α,β-UNSATURATED CARBOXYLIC ACID AND ALDEHYDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| EP-0931060-A1 | SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999031491-A1 | METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999025752-A1 | FUNCTIONALIZED RESIN FOR THE SYNTHESIS OF AMIDES AND PEPTIDES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999000356-A1 | SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | LCAT, CD47, PHOSPHO1 | MEN1 762/4885KMT2A 419/4885PARP1 2883/4885 |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | ACTB, CHERP, EEA1 | MEN1 2434/4885KMT2A 4267/4885PARP1 2910/4885 |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | IGF2BP1, IGF2BP2, IGF2BP3 | MEN1 855/4885KMT2A 1585/4885PARP1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.